HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC

Author(s):

Jonathan Riess, MD, MS, UC Davis Comprehensive Cancer Center,Christine Bestvina, MD, University of Chicago

This episode summarizes the HERTHENA-Lung02 trial and examines the average duration of response to platinum-based chemotherapy in patients with advanced EGFR-mutated NSCLC who have previously undergone multiple lines of EGFR TKI therapy, discusses strategies for community oncologists to tackle diverse resistance mechanisms to third-generation TKIs, and evaluates the importance of tolerability in sparing platinum-based chemotherapy compared with using ADCs in subsequent treatment lines.

EP: 1.Clinical Insights on Osimertinib in Frontline Therapy for EGFR-Mutated NSCLC

EP: 2.Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA

EP: 3.ADAURA Trial Findings: Outcomes and CNS Involvement in EGFR-Mutated NSCLC

EP: 4.Osimertinib in Resected Stage IB to IIIA NSCLC: Perspectives on Its Use for Less Common EGFR Mutations

EP: 5.Tailoring Treatment by Stage: Insights From ADAURA for Stage IB to IIIA EGFR-Mutated NSCLC

EP: 6.Targeted ADCs vs Chemotherapy in Heavily Pretreated NSCLC: Clinical Benefits and Challenges

EP: 7.Role of Datopotamab Deruxtecan in Advanced NSCLC: Insights From TROPION-Lung01

EP: 8.Managing Toxicities With TROP2-Directed ADCs in Advanced NSCLC: Best Practices and Management Strategies

EP: 9.Impressions From TROPION-Lung05: Dato-DXd in Heavily Pretreated Advanced NSCLC

EP: 10.Adverse Event Management and Resistance Mechanisms: Key Considerations for Datopotamab Deruxtecan in Advanced NSCLC

EP: 11.Evaluating Response Rates in HERTHENA-Lung01: Insights on HER3-DXd

EP: 12.Integrating HER3-DXd: Clinical Considerations for Future Approval and Implementation in Practice

Now Viewing

EP: 13.HERTHENA-Lung02 Trial: Exploring the Role of Patritumab Deruxtecan in Advanced EGFR-Mutant NSCLC

EP: 14.Navigating Treatment Choices: Clinically Meaningful Outcomes to Look for in HERTHENA-Lung02

EP: 15.Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

Video content above is prompted by the following:

Please summarize the HERTHENA-Lung02 trial. In your experience, what is the average DOR among your patients with platinum-based chemotherapy on or after treatment with at least 1 line of EGFR TKI therapy for advanced or metastatic EGFR-mutated NSCLC?
How might community oncologists address the diverse mechanisms of resistance to third-generation TKIs to optimize subsequent treatment aftermultiple lines of prior therapy for advanced or metastatic NSCLC with AGAs?
From a tolerability perspective, how important is sparing platinum-based chemotherapy in subsequent lines of therapy vs an ADC?